Medpace released its Q2 2026 earnings on July 22, 2026, with the corresponding investor conference call held on July 23, 2026. The company reported a significant earnings beat, generating $707.3 million in revenue (a 17.2% year-over-year increase) and $4.25 in diluted EPS, outpacing analyst estimates of $690.6 million and $3.98, respectively1. The market reacted with aggressive enthusiasm; the stock surged 17.8% in after-hours trading to approximately $622, nearing its 52-week high of $677.

The primary catalyst for this positive valuation shift was the repair of the company's net book-to-bill ratio, which had collapsed to 0.88x in Q1 2026, causing a severe stock sell-off earlier in the year3. In Q2 2026, net new business awards climbed 28.2% year-over-year to $795.7 million, driving the book-to-bill ratio back up to a highly healthy 1.13x a ...